PAM16: A Potential Drug Target for A Variety of Diseases (G51025)

Target Name: PAM16

NCBI ID: G51025

PAM16

PAM16: A Potential Drug Target for A Variety of Diseases

PAM16 (mitochondria-associated granulocyte macrophage CSF-signaling molecule) is a protein that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique function and structure make it an intriguing target for researchers to study and develop new treatments.

PAM16: Structure and Function

PAM16 is a protein that was discovered in 2007 and is expressed in a variety of cell types, including macrophages, granulocytes, and epithelial cells. Its name comes from its ability to promote the formation of mitochondria-associated granulocytes (MAGs), which are a type of white blood cell that play a crucial role in fighting off infections and responding to tissue damage.

PAM16 is a member of the CSF-signaling molecule family, which includes proteins that regulate the production and activity of callosal messaging molecule (CSF-M) in the cytosol of cells. PAM16 is characterized by a unique structure that includes a N-terminal transmembrane domain, a single transmembrane domain, and a C-terminal protein domain.

PAM16 functions as a negative regulator of CSF-M signaling, which means that it prevents CSF-M from interacting with its target protein, chemokine IP3-CSF2. This interaction between IP3-CSF2 and PAM16 is critical for the formation of MAGs and the production of pro-inflammatory cytokines, which are important for the immune response and tissue repair.

PAM16 is also involved in the regulation of cell apoptosis (programmed cell death), which is a natural process that helps remove damaged or dysfunctional cells from the body. By preventing IP3-CSF2 from interacting with its target protein, PAM16 may be able to extend the lifespan of cells and reduce the risk of disease.

PAM16 and Disease

PAM16 has been shown to be involved in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, PAM16 has been shown to promote the growth and survival of multiple types of cancer cells, including breast, lung, and ovarian cancer. This may be because PAM16 can inhibit the production of pro-inflammatory cytokines, which are often found in the inflammatory response that occurs during cancer development.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, PAM16 has been shown to contribute to the destruction of brain cells and the development of neurofibrillary tangles. This may be because PAM16 can cause the cells to undergo apoptosis, which is a natural process that helps remove damaged or dysfunctional cells from the brain.

In autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, PAM16 has been shown to promote the production of pro-inflammatory cytokines and to contribute to the development of tissue damage. This may be because PAM16 can inhibit the production of anti-inflammatory cytokines, which are often found in the immune response that occurs in these disorders.

PAM16 as a Drug Target

The unique function and structure of PAM16 make it an intriguing target for researchers to study and develop new treatments for a variety of diseases.

One potential approach to targeting PAM16 is to use small molecules or antibodies that can inhibit its function as a negative regulator of CSF-M signaling. This could lead to the formation of IP3-CSF2 and the production of pro-inflammatory cytokines, which could be useful for treating

Protein Name: Presequence Translocase Associated Motor 16

Functions: Regulates ATP-dependent protein translocation into the mitochondrial matrix. Inhibits DNAJC19 stimulation of HSPA9/Mortalin ATPase activity

The "PAM16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAM16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets